RSS Feed
Tags
adaptive trials advertising advisory committees best practices biologics biosimilar biotech BLA cancer Cato BioVentures Cato Research CBER CDER CDRH clinical trials CMC conference DDMAC DIA drug development eCTD efficacy FDA GlobalSubmit guest post guidance IND inspections medical devices NDA NIH nonclinical research oncology outsourcing personalized medicine postmarketing protocol safety slides Social Media statistical analysis transparency venture capital warning letters webinarCategories
Archives
Links
Follow us on Twitter!
- Featured yesterday at Fierce Biotech IT - Cato lists five keys to success in adaptive trials http://bit.ly/aHry0A about 17 hours ago from TweetDeck
- RT @reuters: "Outgunned FDA tries to get tough with drug ads" http://bit.ly/btorHn 08:45:47 PM September 07, 2010 from web
- @MicroConstants Thanks for retweeting! 07:27:43 PM September 07, 2010 from TweetDeckin reply to MicroConstants
- New blog post: August 2010 FDA Guidances - http://ask-cato.com/mg 02:50:26 PM September 07, 2010 from WordTwit Plugin
Tag Archives: biologics
Generic Lovenox – Moving One Step Closer to Biosimilars
We bleed from similar veins. – Tupac Shakur Lovenox is not, I repeat, not a biologic therapeutic. It is derived from a biological source (pig intestines, yum), but it is not protein-based. However, the FDA’s approval of a generic form … Continue reading
Posted in FDA, Industry News
Tagged biologics, biosimilar, drug development, FDA, generic drugs
1 Comment
OIG Report Shows Increasing Use of Foreign Clinical Trials in Marketing Applications (and Challenges for the FDA)
There are no foreign lands. It is the traveler only who is foreign. – Robert Louis Stevenson Global. That’s one of the buzz words/ideas that has gripped modern drug development. In particular, there is a notion that foreign countries represent … Continue reading
Posted in Clinical Trials, FDA, Industry News
Tagged biologics, BLA, clinical trials, drug development, FDA, GCP, IND, inspections, marketing application, NDA
Comments Off
Use A Detailed Development Plan to Secure Venture Capital
This is a guest post by Shane Grivna, Ph.D. Shane is a Clinical Strategy Scientist for Cato Research and an Analyst for Cato BioVentures. It’s a tough time to be asking for money. Whether you’re a highschooler who needs cash … Continue reading
Posted in Guest Posts, Venture Capital
Tagged biologics, business plan, Cato BioVentures, CDRH, development plan, drug development, FDA, venture capital
1 Comment
FDA Ups the Ante on Transparency
Transparency is not the same as looking straight through a building: it’s not just a physical idea, it’s also an intellectual one. – Helmut Jahn I’ve talked about its transparency initiative before (here, here, here, and here), but the FDA’s … Continue reading
Posted in FDA, Industry News
Tagged 510(k), ANADA, ANDA, biologics, BLA, drugs, exclusivity, FDA, medical devices, NADA, NDA, patent, PMA, transparency
2 Comments
FDA Forms Biosimilar Work Group
In the end we are all separate: our stories, no matter how similar, come to a fork and diverge. We are drawn to each other because of our similarities, but it is our differences we must learn to respect. – … Continue reading
Posted in FDA, Industry News
Tagged biologics, biosimilar, CBER, CDER, FDA, Janet Woodcock
1 Comment